コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ralones, including a precursor to Zoloft, an antidepressant drug.
2 acute and chronic pain and as a fast-acting antidepressant drug.
3 ine, a clinically approved antipsychotic and antidepressant drug.
4 Ketamine is a psychotomimetic and antidepressant drug.
5 RF 1 antagonists could be used clinically as antidepressant drugs.
6 ive behaviors, but does hamper the effect of antidepressant drugs.
7 paved the way for the development of modern antidepressant drugs.
8 attempt after starting treatment with newer antidepressant drugs.
9 ding increased risk of suicide with 10 newer antidepressant drugs.
10 factors mediating the behavioral effects of antidepressant drugs.
11 ay be important for the clinical efficacy of antidepressant drugs.
12 action of norepinephrine reuptake inhibitor antidepressant drugs.
13 effects of norepinephrine reuptake inhibitor antidepressant drugs.
14 otential target for the development of novel antidepressant drugs.
15 release, suggesting a mechanism of action of antidepressant drugs.
16 of inescapable stress, and is used to screen antidepressant drugs.
17 rs, aniline derivatives, and basic tricyclic antidepressant drugs.
18 hanism of action of chronically administered antidepressant drugs.
19 ar target for the development of fast-acting antidepressant drugs.
20 processes after chronic treatment with these antidepressant drugs.
21 vity, which may underlie the actions of many antidepressant drugs.
22 ng-term therapeutic effect of anxiolytic and antidepressant drugs.
23 agents, including amphetamines, cocaine, and antidepressant drugs.
24 systems in the manner seen with established antidepressant drugs.
25 isplay high affinities for antipsychotic and antidepressant drugs.
26 naltered in depression, but is influenced by antidepressant drugs.
27 of the neurotransmitter systems targeted by antidepressant drugs.
28 support and counselling and to therapy with antidepressant drugs.
29 e primary target for the action of selective antidepressant drugs.
30 ecessary for some of the clinical effects of antidepressant drugs.
31 te and GABA receptors, which are targets for antidepressant drugs.
32 argets for the development of new classes of antidepressant drugs.
33 literature inflated the apparent efficacy of antidepressant drugs.
34 le characteristics for putative rapid-acting antidepressant drugs.
35 rotonation events and membrane permeation of antidepressant drugs.
36 ogenitor cell proliferation, similar to some antidepressant drugs.
37 RI prescriptions and prescriptions for other antidepressant drugs.
38 ffects on animal behavior tests sensitive to antidepressant drugs.
39 y than a wide spectrum of currently marketed antidepressant drugs.
40 argets for the development of rapidly acting antidepressant drugs.
41 ment of depression and on the development of antidepressant drugs.
42 transporter (SERT) is the primary target for antidepressant drugs.
43 elective serotonin reuptake inhibitor (SSRI) antidepressant drugs.
44 improvement of depression severity with two antidepressant drugs.
45 tion, a population likely to be resistant to antidepressant drugs.
46 r antagonists may be potential anxiolytic or antidepressant drugs.
47 for optimal binding of fluoxetine and other antidepressant drugs.
48 r antagonists may be potential anxiolytic or antidepressant drugs.
49 currently being developed as antiobesity and antidepressant drugs.
50 ctivity, and behavioral responses to chronic antidepressant drugs.
51 -like actions of other putative rapid-acting antidepressant drugs (2R,6R)-hydroxynorketamine (ketamin
52 IMCP increased clinician recommendations for antidepressant drugs, a mental health referral, or both
53 se of depression and that current first-line antidepressant drugs act by restoring excitatory synapti
54 el rodent assay to investigate how different antidepressant drugs act to modify affective biases that
57 urely neurotransmitter-based explanation for antidepressant drug action is challenged by the delayed
58 cepted for its involvement in resilience and antidepressant drug action, is a common genetic locus of
65 , we asked whether chronic treatment with an antidepressant drug (AD) that modifies serotonergic func
67 both groups, during the 20-week experiment, antidepressant drug administration was tapered and disco
68 ese data support the hypothesis that chronic antidepressant drug administration, through regulation o
69 chotropic drugs in current medical practice, antidepressant drugs (ADs) of the selective serotonin re
70 psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect.
71 ent study demonstrates that the mixed action antidepressant drug amitriptyline enhances norepinephrin
73 nt-reported clinician recommendations for an antidepressant drug among nondepressed patients could no
74 l insight into both the pharmacology of this antidepressant drug and the targeting of the alpha(2A)AR
76 rter (NET) is a site of action for tricyclic antidepressant drugs and for drugs of abuse such as amph
77 site of common transcriptional regulation by antidepressant drugs and in both reversing susceptibilit
78 n region-specific actions of a wide range of antidepressant drugs and indicate that pharmacological i
80 ides strong support for the notion that both antidepressant drugs and psychological therapies modify
83 atments might help make best use of existing antidepressant drugs and reduce the number of treatment-
84 cellular and molecular processes affected by antidepressant drugs and their persistence after discont
85 The suicides were divided into those free of antidepressant drugs and those in whom prescription of a
86 on-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that impl
87 ention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing
88 T is the major binding site in the brain for antidepressant drugs, and it also binds amphetamines and
89 mechanisms of both typical and rapid-acting antidepressant drugs, and recent findings have started t
90 ndings that the analgesic effects of various antidepressant drugs are differentially dependent on the
92 The classical targets for antipsychotic and antidepressant drugs are G protein-coupled receptors and
93 ay contribute to the therapeutic efficacy of antidepressant drugs are likely to occur over distances
95 However, no published evidence exists that antidepressant drugs are safe or efficacious in patients
98 n be reversed by treatment with conventional antidepressants drugs, as well as by subanesthetic doses
99 th week of gestation nor the use of non-SSRI antidepressant drugs at any time during pregnancy was as
100 lecular mechanisms by which various types of antidepressant drugs bind and inhibit SERT and NET are s
101 ment of depression, the molecular details of antidepressant drug binding are still not fully understo
102 d a high-throughput screen and found that an antidepressant drug, bupropion, counteracts glucotoxicit
103 s are less likely to respond to conventional antidepressant drugs, but novel immune-based therapeutic
104 athway has been implicated in the actions of antidepressant drugs, but studies to date have not demon
105 (SSRIs) are the most commonly used class of antidepressant drugs, but the cellular and molecular mec
106 ST), the most used assay to screen potential antidepressant drugs by decreasing immobility behavior.
107 ained lay health counsellor, supplemented by antidepressant drugs by the primary care physician and s
109 these disorders, but it is not known whether antidepressant drugs can directly modulate the neural pr
111 ynorketamine [(2R,6R)-HNK] is a rapid-acting antidepressant drug candidate with limited dissociation
114 ificant effect of CBT during continuation of antidepressant drugs compared with antidepressants alone
115 on, but reduced availability in those taking antidepressant drugs, consistent with a possible mode of
117 r alone or as add-on therapy to conventional antidepressant drugs, could help to relieve depressive s
118 The effects of chronic administration of the antidepressant drugs desipramine, nortryptiline and paro
120 we review the current state of rapid-acting antidepressant drug development, including NMDA channel
128 s defined from at least two switches between antidepressant drugs, each prescribed for at least 6 wee
129 monstration of genetic variation influencing antidepressant drug effects on emotional processing in h
131 and Western blot analysis revealed that all antidepressant drugs elicited an anatomically specific i
132 after 8 weeks of treatment with one of three antidepressant drugs (escitalopram, sertraline, or venla
134 recent advances in our understanding of how antidepressant drugs exert their antinociceptive effects
136 nd selectivity over NET for the prototypical antidepressant drug fluoxetine (Prozac; Eli Lilly, India
137 ubsequent study of TrkB interaction with the antidepressant drug fluoxetine, and the antipsychotic dr
141 e subdivided into those who had been free of antidepressant drugs for at least 3 months and those in
142 e subdivided into those who had been free of antidepressant drugs for at least three months, and thos
143 860 outpatients were screened, yielding 199 antidepressant drug-free patients with unipolar nonpsych
144 ; p<0.002), and the three patients taking an antidepressant drug had globally reduced [(18)F]GE-179 V
146 es of the therapeutic mechanism of action of antidepressant drugs have focused on the role of the mon
147 hat ketamine, an anesthetic and rapid-acting antidepressant drug, holds promise as a candidate for OU
151 fluoxetine is the most frequently prescribed antidepressant drug in the United States, its safety in
152 ract risk after exposure to SSRI or to other antidepressant drugs in a large electronic primary care
153 mice mimicked the effects of anxiolytic and antidepressant drugs in a number of behavioral tests, wi
158 nty and controversy remains about the use of antidepressant drugs in the management of depressive epi
159 dysfunction, suggesting a potential for such antidepressant drugs in the treatment of presymptomatic
160 Importantly, the analgesic effect of several antidepressant drugs, including selective serotonin reup
161 c-like actions of several monoamine-directed antidepressant drugs, including tricyclic antidepressant
163 gy.SIGNIFICANCE STATEMENT The anesthetic and antidepressant drug ketamine is well-characterized as an
164 and discovers a novel mechanism by which the antidepressant drug ketamine promotes long-term improvem
165 ST neurons in the prelimbic cortex (PLC) had antidepressant drug-like effects on anxiety- and anhedon
167 fic comorbid conditions and sustained use of antidepressant drugs may be associated with a medical-of
168 Although an infrequent event, DILI from antidepressant drugs may be irreversible, and clinicians
169 te mechanism of action, and may inform novel antidepressant drug mechanisms that could yield superior
170 s unclear how the 5-HT signalling effects of antidepressant drugs might alter neuropsychological mech
171 on and subsequently develop more efficacious antidepressant drugs, multiple theories have been propos
172 second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has
175 the previously shown biphasic action by the antidepressant drugs on total BDNF expression is explain
176 ssive phenotypes, which can be alleviated by antidepressant drugs or by overexpression of TrkB in the
177 between behavioral modifications induced by antidepressant drugs or environmental enrichment and cha
178 n or elimination of REM sleep in subjects on antidepressant drugs or with brainstem lesions produces
179 imulation, exercise, dietary restriction and antidepressant drugs preserve brain function during agin
180 s, the finding that long-term treatment with antidepressant drugs produces an increase in neurogenesi
181 uoxetine (FLX), the active ingredient of the antidepressant drug Prozac, inhibits reuptake of the neu
182 ecent surprising findings have revealed that antidepressant drugs reactivate a window of juvenile-lik
183 nthetic approach to the stereoisomers of the antidepressant drug reboxetine and its implementation to
184 ssessment of clinician- and patient-reported antidepressant drug recommendation (primary outcomes) wi
185 of the composite measure of patient-reported antidepressant drug recommendation, mental health referr
186 strate that fluoxetine, unlike several other antidepressant drugs, reduces Alu RNA-induced RPE degene
187 reclinical findings that classical and novel antidepressant drugs relieve the symptoms of depression
189 peutic strategies exist for depression, most antidepressant drugs require several weeks before reachi
190 d in studies of antipsychotic drug efficacy, antidepressant drug response, and drug-induced adverse e
193 e reuptake inhibitor, is a widely prescribed antidepressant drug routinely detected in the aquatic en
194 breastfeeding is not necessary, because most antidepressant drugs seem not to affect the infant.
195 istration of paroxetine, a widely prescribed antidepressant drug that acts by inhibiting reuptake of
196 eatment with fluoxetine, a widely prescribed antidepressant drug that is known to promote the activat
197 ne, and abolishes the effects of widely used antidepressant drugs that act as catecholamine reuptake
198 nile rats acutely and chronically exposed to antidepressant drugs that act on serotonin and norepinep
199 are implicated in psychiatric disorders, and antidepressant drugs that block the NE transporter (NET)
200 promise as lead compounds in the search for antidepressant drugs that release serotonin rather than
202 ther these behaviours are sensitive to human antidepressant drugs; the striped shore crab, Pachygraps
205 using patient characteristics to tailor the antidepressant drug therapy is associated with an increa
206 l crying, which has been shown to respond to antidepressant drug therapy, the other post-stroke emoti
208 ide, and because long-term administration of antidepressant drugs to rats down-regulates these protei
214 icidal ideation and behavior associated with antidepressant drug treatment in children and adolescent
216 that combined psychological intervention and antidepressant drug treatment may not be more effective
217 s support careful clinical monitoring during antidepressant drug treatment of severely depressed youn
218 affects transcription and may be involved in antidepressant drug treatment outcome, although response
221 children and adolescents (aged 6-18 years), antidepressant drug treatment was significantly associat
230 e associated with the mechanism of these two antidepressant drug treatments and may contribute to the
231 or dependence comorbidity, suicide attempts, antidepressant drug use, and having a relative with rapi
233 ynchrony system in yeast with phenelzine, an antidepressant drug used in the treatment of affective d
236 ssion who had been successfully treated with antidepressant drugs were randomly assigned to either CB
237 ar follow-up was undertaken, during which no antidepressant drugs were used unless a relapse ensued.
239 0.1 mg/kg), outperforming commonly available antidepressant drugs, while compound 16 elicited a robus
240 r future structure-based drug development of antidepressant drugs with fine-tuned transporter selecti
241 itive transporters, as novel targets for new antidepressant drugs with improved therapeutic potential
242 aradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.
243 mal elderly participants who were exposed to antidepressant drugs within the past 5 y to participants